Renjitha Bhaskaran who has M.Sc. degree in Biostatistics joined as Lecturer in the Department of Biostatistics, School of Medicine, Kochi on 10th November 2014. She had worked as Guest Lecturer in biostatistics at St.Thomas College Palai from 12-01-2011 to 02-11-2014 and undergone job training on Pharmacognosy as part of her  Bachelor Degree in Botany (Vocational Model-2) Course in Nagarjuna. She had done three research projects at Regional Cancer Center Thiruvananthapuram, St.Mary’s Hospital Thodupuzha and Newman College, Thodupuzha respectively.


Publication Type: Journal Article

Year of Publication Title


K. D. Salima, Dr Rajesh Gopalakrishna, Renjitha Bhaskaran, and R., R. P., “Physician Preference of Anti-diabetic Medications and Complications in Pancreatic Diabetes - An Experience from A Tertiary Care Teaching Hospital”, Research Journal of Pharmacy and Technology, Raipur, vol. 12, no. 3, 2019.[Abstract]

<p>Aim: There are no guidelines for use of diabetic medications in pancreatic diabetes. Hence we attempted to the<br />benefits of antidiabetic agents in pancreatic diabetes. Materials and methods: a total of 670 chronic pancreatitis<br />patients are selected. Out of that about 126 patients with pancreatic diabetic are selected for the study. The data<br />collected from 2010. Results: In this study mean age was found to be 53.86&plusmn;12.53. The male patients (73.8%)<br />were more predominant in this study than female patients (26.2%). The complications of chronic pancreatitis<br />among 126 patients, 126 (100) patient had diabetes mellitus (DM), 100 (79) patients had pain. Among 126<br />patients 52 (41.3%) patients had taken insulin only, 21 (16.7%) patients had taken insulin+ oral combination, 16<br />(12.7%) patients had taken Biguanides, 13 (10.3%) of patients had taken oral combinations, 13 (10.3%) patients<br />had taken alpha glucosidase inhibitors, 11 (8.7%) patients who are taken sulfonyl ureas. Most of the patients<br />took insulin monotherapy. Conclusion: Insulin was most preferred agent. Metformin was the most commonly<br />preferred oral antidiabetic agent.</p>

More »»


Rajesh Jose, Shetty, A., Krishna, N., Chathoth, V., Renjitha Bhaskaran, Jayant, A., and Dr. Praveen Varma, “Early and Mid-Term Outcomes of Patients Undergoing Coronary Artery Bypass Grafting in Ischemic Cardiomyopathy.”, J Am Heart Assoc, vol. 8, no. 10, p. e010225, 2019.[Abstract]

Background Many observational studies and trials have shown that coronary artery bypass grafting improves the survival in patients with ischemic cardiomyopathy. However, these results are based on data generated from developed countries. Poor socioeconomic statuses, lack of uniformity in healthcare delivery, differences in risk profile, and affordability to access optimal health care are some factors that make the conclusions from these studies irrelevant to patients from India. Methods and Results One-hundred and sixty-two patients with severe left ventricular dysfunction (ejection fraction ≤35%) who underwent coronary artery bypass grafting from 2009 to 2017 were enrolled for this study. Mean age of the study population was 58.67±9.70&nbsp;years. Operative mortality was 11.62%. Thirty day/in-house composite outcome of stroke and perioperative myocardial infarction were 5.8%. The percentage of survival for 1&nbsp;year was 86.6%, and 5-year survival was 79.9%. Five-year event-free survival was 49.3%. The mean ejection fraction improved from 30.7±4.08% (range 18-35) to 39.9±8.3% (range 24-60). Lack of improvement of left ventricular function was a strong predictor of late mortality (hazard ratio, 21.41; CI 4.33-105.95). Even though there was a trend towards better early outcome in off-pump CABG , the 5-year survival rates were similar in off-pump and on-pump group (73.4% and 78.9%, respectively; P value 0.356). Conclusions We showed that coronary artery bypass grafting in ischemic cardiomyopathy was associated with high early composite outcomes. However, the 5-year survival rates were good. Lack of improvement of left ventricular function was a strong predictor of late mortality.

More »»


R. Prabhu, Renjitha Bhaskaran, Shenoy, V., G, R., and Sidharthan, N., “Clinical characteristics and treatment outcomes of primary autoimmune hemolytic anemia: a single center study from South India.”, Blood Res, vol. 51, no. 2, pp. 88-94, 2016.[Abstract]

<p><b>BACKGROUND: </b>Autoimmune hemolytic anemia (AIHA) is a less recognized, potentially fatal condition. There is a scarcity of data on clinicoserological characteristics and response to therapy concerning this disease from South India.</p><p><b>METHODS: </b>Data for 33 patients with primary AIHA recorded from July 2009 to June 2015 were retrospectively analyzed for clinical presentation, response to frontline therapy, durability of response, time to next treatment (TTNT), and response to second-line agents.</p><p><b>RESULTS: </b>The median follow-up period was 50 months. Among 33 patients, 48% of the cases were warm autoimmune hemolytic anemia (WAIHA), 46% were cold agglutinin disease (CAD), and 6% were atypical. Three-fourth of patients had severe anemia (<8 g/dL hemoglobin [Hb]) at onset; younger patients (age <40 yr) had more severe anemia. All of the patients who required treatment received oral prednisolone at 1.5 mg/kg/d as a frontline therapy, and the response rate was 90% (62% complete response [CR] and 28% partial response [PR]). The overall response to corticosteroids in WAIHA and CAD was 87% and 92%, respectively. The median corticosteroid duration was 14 months, and 50% of the patients required second-line agents. Fourteen patients received azathioprine as a second-line agent, and 11 of these patients responded well, with half of them not requiring a third agent. Four patients developed severe infections (pneumonia, sepsis, and soft tissue abscess) and two had life-threatening venous thrombosis. One case of death was recorded.</p><p><b>CONCLUSION: </b>AIHA is a heterogeneous disease that requires care by physicians experienced in treating these patients.</p>

More »»